Supplementary Balance Sheet Information

3 Months Ended

Mar. 31, 2023

Balance Sheet Related Disclosures [Abstract]

Note 5 – Supplementary Balance Sheet Information

Property and equipment consist of the following (in thousands):



	March 31, 2023			December 31, 2022
Lab equipment	$	6,036		$	6,035
Leasehold improvements		2,365			2,365
Computer equipment		837			749
Furniture and fixtures		349			349
Software		324			324
Vehicles		97			97
Construction in process		10,397			2,947
		20,405			12,866
Less accumulated depreciation		(7,308	)		(7,018	)
Total property and equipment, net	$	13,097		$	5,848

Depreciation expense for the three months ended March 31, 2023 and 2022 was $0.3 million and $0.4 million, respectively.

Intangible assets, excluding goodwill, consist of the following (in thousands):


	March 31, 2023							December 31, 2022
	Cost		Accumulated Amortization			Net Carrying Value		Cost		Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization
Patents	$	1,889	$	(673	)	$	1,216	$	1,880	$	(647	)	$	1,233
Purchased technology		16,900		(8,919	)		7,981		16,900		(8,450	)		8,450
Intangible assets not subject to amortization
Trademarks		114		—			114		114		—			114
Total	$	18,903	$	(9,592	)	$	9,311	$	18,894	$	(9,097	)	$	9,797

Amortization expense related to definite-lived intangible assets was $0.5 million for both the three months ended March 31, 2023 and 2022, respectively.

Future estimated amortization expense of intangible assets is (in thousands):


	As of March 31, 2023
Remainder of 2023	$	1,483
2024		1,969
2025		1,963
2026		1,949
2027		998
2028 and thereafter		835
Total	$	9,197

Accrued liabilities consist of the following (in thousands):



	March 31, 2023		December 31, 2022
Compensation related accruals	$	3,088	$	4,671
Accrued clinical trial expense		1,177		1,232
Other expenses		1,475		2,315
Total accrued liabilities	$	5,740	$	8,218